The purpose of this trial is to find out whether an experimental drug provides cardiovascular protection or does not increase risk to the heart and blood vessels when used in patients living with overweight or obesity. We want to look at this in patients living with overweight or obesity who have risk factors for cardiovascular disease or established cardiovascular or chronic kidney disease. To do this we will look at the effect on the heart and blood vessels by counting the number of cardiovascular events (e.g., heart attack or stroke) that happens in people during this study. Participants will be placed on a weight loss and physical activity regimen and change in body weight will be tracked.


Currently recruiting participants: No

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 150

Inclusion criteria:

-BMI ≥27 kg/m2 with established heart disease and/or at least 2 weight related
complications OR
-participants with BMI ≥30 kg/m2 with established heart or kidney disease and/or at least
2 weight-related complications

Exclusion criteria:

Previous treatment with a GLP-1R (for example, Ozempic)


Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

Michelle Smith

Principal investigator:

David Lau

Clinical trial: